

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

CLAIMS

1-4. (Cancelled).

5. (Currently Amended) A method of treating an inflammatory disease in a mammal, which comprises administering to the mammal an anti-inflammatory agent consisting of a monovalent antibody fragments antigen-binding fragment of an antibody directed against the EC2 domain of the FcαRI receptor.

6. (Canceled)

7. (Withdrawn) The method of claim 5, wherein the inflammatory disease is selected from the group consisting of lupus, rheumatoid arthritis, diabetes, nephritis renal fibrosis, obstructive nephropathy and gut inflammatory disorders.

8. (Previously Presented) The method of claim 5, wherein the inflammatory disease is an allergy.

9. (Previously Presented) The method of claim 8, wherein the allergy is asthma.

10. (Previously Presented) The method of claim 5, whereby IgG-induced phagocytosis is inhibited.

11. (Previously Presented) The method of claim 10, whereby IgE-mediated exocytosis is further inhibited.

12. (Currently Amended) The method of claim 9, whereby antigen-induced bronchial hyper-reactivity is ~~prevented~~ reduced.

13. (Previously Presented) The method of claim 5, wherein the monovalent antibody fragments are administered in a form of a composition.

14. (Previously Presented) The method of claim 13, wherein the composition is administered by injection.

15. (Previously Presented) The method of claim 14, wherein the injection is intramuscular, intradermal, intravenous, intraperitoneal or subcutaneous.

16. (Previously Presented) The method of claim 13, wherein the composition is administered by aerosol.

17. (Previously Presented) The method of claim 5, wherein the mammal is human.

18. (Previously Presented) The method of claim 5, wherein the antibody fragments are Fab fragments of an anti- Fc α RI mAb.

19. (Previously Presented) The method of claim 18, wherein the anti- Fc α RI mAb is (IgG1k, clone A 77).

20. (Withdrawn) A pharmaceutical composition, comprising:

- a) monovalent antibody fragments directed against mammalian Fc α RI receptor, and
- b) a carrier.

21. (Withdrawn) The pharmaceutical composition of claim 20, in a form suitable for injection.

22. (Withdrawn) The pharmaceutical composition of claim 20, in a form suitable for inhalation.

23. (Withdrawn) The pharmaceutical composition of claim 20, wherein the monovalent antibody fragments are directed against EC2 domain of the Fc α RI receptor.

24. (Withdrawn) The pharmaceutical composition of claim 20, wherein the antibody fragments are of an anti- Fc α RI mAb.

25. (Withdrawn) The pharmaceutical composition of claim 24, wherein the anti- Fc α RI mAb is (IgG1k, clone A 77).